Press "Enter" to skip to content

FDA approves first treatment for rare blood disease

The FDA approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.

Original source: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm629020.htm

Also Read:   Coronavirus (COVID-19) Update: Daily Roundup September 30, 2020